Hematopoietic cell transplantation (HCT) is a potentially curative treatment for many
hematologic and nonhematologic disorders. Graft-versus-host-disease (GVHD) in its acute
or chronic form remains the most important nonrelapse post-HCT complication. Biomarkers
offer objective, unbiased information on systemic disorders, and significant attention has
focused on identifying biomarkers for GVHD. Ideally, a GVHD biomarker is actionable, with
the results of biomarker testing used to guide clinical management of disease and clinical …